BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 14711368)

  • 1. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
    Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
    Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
    Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
    Leslie NR; Bennett D; Gray A; Pass I; Hoang-Xuan K; Downes CP
    Biochem J; 2001 Jul; 357(Pt 2):427-35. PubMed ID: 11439092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.
    Koul D; Jasser SA; Lu Y; Davies MA; Shen R; Shi Y; Mills GB; Yung WK
    Oncogene; 2002 Apr; 21(15):2357-64. PubMed ID: 11948419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
    Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
    Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.
    Downes CP; Walker S; McConnachie G; Lindsay Y; Batty IH; Leslie NR
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):338-42. PubMed ID: 15046604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate.
    Campbell RB; Liu F; Ross AH
    J Biol Chem; 2003 Sep; 278(36):33617-20. PubMed ID: 12857747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids.
    McConnachie G; Pass I; Walker SM; Downes CP
    Biochem J; 2003 May; 371(Pt 3):947-55. PubMed ID: 12534371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.
    Georgescu MM; Kirsch KH; Kaloudis P; Yang H; Pavletich NP; Hanafusa H
    Cancer Res; 2000 Dec; 60(24):7033-8. PubMed ID: 11156408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TPIP: a novel phosphoinositide 3-phosphatase.
    Walker SM; Downes CP; Leslie NR
    Biochem J; 2001 Dec; 360(Pt 2):277-83. PubMed ID: 11716755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes.
    Ono H; Katagiri H; Funaki M; Anai M; Inukai K; Fukushima Y; Sakoda H; Ogihara T; Onishi Y; Fujishiro M; Kikuchi M; Oka Y; Asano T
    Mol Endocrinol; 2001 Aug; 15(8):1411-22. PubMed ID: 11463863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the PTEN phosphatase.
    Gericke A; Munson M; Ross AH
    Gene; 2006 Jun; 374():1-9. PubMed ID: 16675164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.
    Raftopoulou M; Etienne-Manneville S; Self A; Nicholls S; Hall A
    Science; 2004 Feb; 303(5661):1179-81. PubMed ID: 14976311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo analysis of 3-phosphoinositide dynamics during Dictyostelium phagocytosis and chemotaxis.
    Dormann D; Weijer G; Dowler S; Weijer CJ
    J Cell Sci; 2004 Dec; 117(Pt 26):6497-509. PubMed ID: 15572406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The INPP4B paradox: Like PTEN, but different.
    Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
    Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN and Other PtdIns(3,4,5)P
    Csolle MP; Ooms LM; Papa A; Mitchell CA
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33276499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.
    Georgescu MM; Kirsch KH; Akagi T; Shishido T; Hanafusa H
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10182-7. PubMed ID: 10468583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A voltage-sensing phosphatase, Ci-VSP, which shares sequence identity with PTEN, dephosphorylates phosphatidylinositol 4,5-bisphosphate.
    Iwasaki H; Murata Y; Kim Y; Hossain MI; Worby CA; Dixon JE; McCormack T; Sasaki T; Okamura Y
    Proc Natl Acad Sci U S A; 2008 Jun; 105(23):7970-5. PubMed ID: 18524949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.
    Lee JO; Yang H; Georgescu MM; Di Cristofano A; Maehama T; Shi Y; Dixon JE; Pandolfi P; Pavletich NP
    Cell; 1999 Oct; 99(3):323-34. PubMed ID: 10555148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
    Steelman LS; Bertrand FE; McCubrey JA
    Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.